Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes

Research output: Contribution to journalReview articlepeer-review

15 Downloads (Pure)

Abstract

The therapeutic potential of venom-derived drugs is evident today. Currently, several significant drugs are FDA approved for human use that descend directly from animal venom products, with others having undergone, or progressing through, clinical trials. In addition, there is growing awareness of the important cosmeceutical application of venom-derived products. The success of venom-derived compounds is linked to their increased bioactivity, specificity and stability when compared to synthetically engineered compounds. This review highlights advancements in venom-derived compounds for the treatment of diabetes and related disorders. Exendin-4, originating from the saliva of Gila
monster lizard, represents proof-of-concept for this drug discovery pathway in diabetes. More recent evidence emphasises the potential of venom-derived compounds from bees, cone snails, sea anemones, scorpions, snakes and spiders to effectively manage glycaemic control. Such compounds could represent exciting exploitable scaffolds for future drug discovery in diabetes, as well as providing tools to allow for a better understanding of cell signalling pathways linked to insulin secretion and metabolism.
Original languageEnglish
Pages (from-to)1-13
JournalClinical Medicine Insights: Endocrinology and Diabetes
Volume14
Early online date27 Mar 2021
DOIs
Publication statusE-pub ahead of print - 27 Mar 2021

Keywords

  • Clinical trials
  • diabetes
  • exendin-4
  • venom therapeutics

Fingerprint

Dive into the research topics of 'Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes'. Together they form a unique fingerprint.

Cite this